Novo Nordisk $NOVO-B.CO, the Danish pharmaceutical giant behind the blockbuster weight-loss drug Wegovy, announced on Thursday its plan to begin late-stage clinical trials for both injectable and oral formulations of amicretin, a novel GLP-1 analog. These Phase III trials, expected to launch in Q1 2026, will target adults with overweight and obesity, expanding the company’s foothold in the rapidly growing global obesity therapeutics market.